Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/29/22
End: 01/15/23
Due: 01/15/24
Phase: N/A
Priority: Normal
Start: 01/13/22
End: 02/14/23
Due: 02/14/24
Phase: N/A
Priority: Normal
Start: 01/31/23
End: 06/30/23
Due: 06/30/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects | NCT05619770 | 101 Therapeutics | user2@example.com | None | 2022-10-29 | 2023-01-15 | 2024-01-15 | - | - | 2025-07-14 |
| A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care | NCT05195749 | 101 Therapeutics | user2@example.com | None | 2022-01-13 | 2023-02-14 | 2024-02-14 | - | - | 2025-07-14 |
| 101-PGC-005 for the Treatment of COVID-19 | NCT05656521 | 101 Therapeutics | user2@example.com | None | 2023-01-31 | 2023-06-30 | 2024-06-30 | - | - | 2025-07-14 |